NanoViricides learns the early study results for anti-flu drug FluCide-I

By Elaine Rigoli

Tampa, Fla., Feb. 27 - NanoViricides, Inc. announced Monday that it has been informed of the initial test results of a nanoviricide compound used in its anti-influenza drug, FluCide-I.

Although the complete written report on these test results will be received in about three weeks, the company said it is excited with the initial reported results.

The company will provide a complete update on these studies as soon as the full report is received and studied, according to a company news release.

In preparation for its upcoming trip to Vietnam, the company conducted this study to establish certain performance characteristics of its nanoviricide compound.

The test was a blind study on mice with H2N1 (common influenza) performed at a prestigious institute, the release said.

"These initial results exceeded our expectations and indicate we are on target to meet the priority goal set by management to develop the world's leading therapeutics for influenza A and bird flu," NanoViricides president Anil Diwan said in a company statement.

The company had previously announced the signing of a memorandum of understanding with the government of Vietnam for the development of bird flu and rabies drugs.

Located in West Haven, Conn., NanoViricides is a development-stage company that is creating special-purpose nanomaterials for antiviral therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.